INSM Earnings Prediction
The chart below shows how INSM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, INSM sees a +1.25% change in stock price 10 days leading up to the earnings, and a +0.47% change 10 days following the report. On the earnings day itself, the stock moves by +0.39%. This data can give you a slight idea of what to expect for the next quarter's release.
INSM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
93.42M
18.15%
3.41%
Gross Margin
75.99%
-1.67%
0.78%
Operating Margin
-212.73%
21.30%
3.77%
Net Margin
-236.04%
17.43%
-29.06%
EPS
-1.27
-14.41%
-34.54%
No Data Available
INSM Earnings Analysis
Insmed, Inc. Corporation (INSM.O) Earnings Conference Call
Positive
Record Quarterly Revenue: 1. Record Revenue Growth: Insmed achieved global net revenues of $93.4 million in Q3 2024, reflecting an 18% year-over-year growth, marking the highest quarterly sales for ARIKAYCE in its history.
U.S. Sales Surge: 2. Strong U.S. Sales Performance: U.S. net revenue for ARIKAYCE was $66.9 million, up 13% compared to the prior year, driven by continued strength in new patient starts.
International Revenue Surge: 3. Significant International Growth: In Japan, net revenue reached $21 million, representing a 31% increase year-over-year, fueled by higher new patient starts and strong treatment continuation rates.
Sales Force Expansion: 4. Expanded Sales Force: Insmed successfully trained and deployed 120 new U.S. sales representatives, bringing the total to 184, enabling comprehensive coverage of pulmonologists across the U.S. for the upcoming brensocatib launch.
Strong Cash Reserves: 5. Robust Cash Position: As of the end of Q3 2024, Insmed reported approximately $1.5 billion in cash, cash equivalents, and marketable securities, an increase of $221 million since the previous quarter, enhancing its financial stability for future growth.
Negative
Cash Burn Increase: 1. Increased Cash Burn: Insmed reported an underlying cash burn of approximately $166 million in Q3 2024, which is higher than recent quarters, indicating increased operational costs as they prepare for the potential launch of brensocatib.
R&D Investment Impact: 2. High R&D Expenses: Research and development expenses reached $150.8 million in Q3 2024, reflecting significant investment in ongoing clinical trials and product development, which may strain financial resources.
SG&A Expense Increase: 3. SG&A Expense Growth: Selling, general, and administrative expenses were $118.9 million in Q3 2024, driven by the expansion of the sales force and preparations for the brensocatib launch, indicating rising operational costs.
Regulatory Approval Uncertainty: 4. Low Probability of Accelerated Approval: Insmed indicated a less than 25% probability of receiving accelerated approval for ARIKAYCE's label expansion, reflecting uncertainty in regulatory outcomes that could impact future revenue.
Future Revenue Dependence: 5. Dependence on Future Revenue from Brensocatib: The company acknowledged that they do not have sufficient cash to fund operations until profitability is achieved, highlighting reliance on future revenue from brensocatib to sustain operations.
INSM FAQs
How does INSM typically perform around its earnings report dates?
Is Insmed Incorporated (INSM) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
INSM Earning Call Sentiment
Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
INSM.O
2.27%Positive
The earnings call highlights strong financial performance with 18% YoY revenue growth, a solid cash position of $1.5 billion, and effective cost management. Despite risks in clinical trials, the company has a strategic sales force expansion and a promising pipeline, particularly for brensocatib. The Q&A reveals high interest in sales roles and a focus on minimizing dilution. Although management was vague about pricing and timelines, the overall sentiment is positive, with potential catalysts like priority review for brensocatib and strong market demand for ARIKAYCE. The stock is likely to see a 2-8% increase.
